Allergy Therapeutics PLC (AIM:AGY)'s (Allergy Therapeutics PLC (AIM:AGY)) Manuel Llobet and Nick Wykeman discuss the interim results for the six months ended 31 December 2021.
And preparations to enter the US later this year with the launch of two clinical trials for the lead allergy immunotherapy programmes.
The firm is also starting the first in human trial of a peanut allergy vaccine and explain some of the results they've had in so far.
They go on to detail how the VLP Peanut treatment is different from other therapies that allergy sufferers are currently using.
A pivotal Phase III trial of their short-course grass pollen immunotherapy is also starting this year which is the final stage ahead of a potential regulatory approval. The team present the market opportunity for this.